下一代影像驱动的新诊断前列腺癌患者分期上调的预后作用
该前瞻性队列纳入100例活检证实的中高危前列腺癌患者,均接受常规影像与PSMA PET/CT分期但按常规影像分期治疗。PSMA PET/CT使26.8%患者分期上调、6.1%下调;中位随访6个月,手术患者中22/83(26.5%)出现生化复发,PSMA PET/CT驱动的分期上调是生化复发无生存期的独立预测因子(HR 3.41,95%CI 1.21-9.56,p=0.019)。
要点
- PSMA PET/CT较常规影像使26.8%患者分期上调、6.1%下调。
- 常规影像因骨转移排除手术者中50%若按PSMA PET/CT可接受根治性治疗。
- PSMA PET/CT分期上调是生化复发的独立预测因子(HR 3.41)。
核心结论
- 应用下一代影像进行分期可改善生化复发无生存期的预测。
- 作者认为,尽管仍需III期证据,下一代影像可能比系统治疗更能识别可从局部治疗获益的患者。
研究设计与样本
- 前瞻性纳入100例活检证实的中高危前列腺癌患者,均接受常规影像和PSMA PET/CT分期,但按常规影像分期进行治疗。
- 评估分期迁移现象的频率,并将分期迁移作为生化复发无生存期的预测因子进行分析。
- 影像后3例患者失访。
主要发现
- PSMA PET/CT较常规影像使26.8%患者分期上调,使6.1%患者分期下调。
- 常规影像因骨转移被排除手术的患者中,50%若由PSMA PET/CT指导治疗选择将接受根治性 intent 治疗。
- 手术患者中位随访6个月,22/83(26.5%)出现生化复发。
- PSMA PET/CT驱动的分期上调显著增加生化复发风险(HR 3.41,95%CI 1.21-9.56,p=0.019)。
- 在单变量和多变量模型中纳入分期迁移,确定PSMA PET/CT分期上调为生化复发无生存期的独立预测因子。
关键数值与推荐
- PSMA PET/CT分期上调对比常规影像:分期上调率26.8%,下调率6.1%。
- 手术患者中位随访6个月,生化复发率22/83(26.5%)。
- PSMA PET/CT驱动分期上调预测生化复发:HR 3.41(95%CI 1.21-9.56,p=0.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出由于缺乏结局数据,下一代影像引入常规临床实践仍存在争议。
- 原文指出仍需III期证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Phase III evidence showed that next-generation imaging (NGI), such as prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), provides higher diagnostic accuracy than bone scan and contrast-enhanced computed tomography (conventional imaging, CI) in the primary staging of intermediate-to-high-risk prostate cancer (PCa) patients. However, due to the lack of outcome data, the introduction of NGI in routine clinical practice is still debated. Analysing the oncological outcome of patients upstaged by NGI (though managed according to CI) might shed light on this issue, supporting the design of randomised trials comparing the effects of treatments delivered based on NGI vs. CI. METHODS: We prospectively enrolled a cohort of 100 biopsy-proven intermediate-to-high-risk PCa patients staged with CI and PSMA PET/CT (though managed according to the CI stage), to assess the frequency of the stage migration phenomenon. Stage migration was then assessed as biochemical recurrence-free survival (bRFS) predictor. RESULTS: Three patients were lost at follow-up after imaging. PSMA PET/CT upstaged 26.8% of patients compared to CI, while it downstaged 6.1% of patients. Notably, 50% of patients excluded from surgery due to the presence of bone metastases at CI would have been treated with radical-intent approaches if PSMA PET/CT had guided the treatment choice. After a median follow-up of 6 months of surgically treated patients, 22/83 (26.5%) had biochemical recurrence (BCR). PSMA PET/CT-driven upstaging determined a significant risk increase for BCR (HR:3.41, 95%CI:1.21-9.56, p = 0.019). Including stage migration in a univariable and multivariable model identified PSMA PET/CT-upstaging as an independent predictor of bRFS. CONCLUSIONS: In conclusion, implementing NGI for staging purposes improves the prediction of bRFS. Although phase III evidence is still needed, this advancement suggests that NGI may better identify patients who would benefit from local treatments than those who may achieve better oncological outcomes through systemic treatment.
引用
- Bauckneht M, Checcucci E, Cisero E, et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37935995. doi:10.1007/s00259-023-06490-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。